1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus Infections - Pipeline Review, H2 2020, provides an overview of the Respiratory Syncytial Virus Infections (Infectious Disease) pipeline landscape.
Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 13, 12, 2, 55, 23 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 10 and 7 molecules, respectively.
Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Respiratory Syncytial Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Respiratory Syncytial Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionRespiratory Syncytial Virus Infections - Overview
Respiratory Syncytial Virus Infections - Therapeutics Development
Respiratory Syncytial Virus Infections - Therapeutics Assessment
Respiratory Syncytial Virus Infections - Companies Involved in Therapeutics Development
Respiratory Syncytial Virus Infections - Drug Profiles
Respiratory Syncytial Virus Infections - Dormant Projects
Respiratory Syncytial Virus Infections - Discontinued Products
Respiratory Syncytial Virus Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abhelix LLC, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advac LLC, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advance Vaccine Laboratories Pty Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Airway Therapeutics LLC, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlloVir Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Anima Biotech Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ark Biosciences Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Atea Pharmaceuticals Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Atriva Therapeutics GmbH, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by AVM Biotechnology LLC, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Beijing Advaccine Biotechnology Company Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by BioComo Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Blue Lake Biotechnology Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by BlueWillow Biologics Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by BravoVax Co Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Calder Biosciences Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Cidara Therapeutics Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Clover Biopharmaceuticals, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies SA, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals Inc, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enyo Pharma SA, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Exopharm Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co Ltd, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2020
- Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abhelix LLC
- Abivax SA
- ADMA Biologics Inc
- Advac LLC
- Advance Vaccine Laboratories Pty Ltd
- Airway Therapeutics LLC
- AlloVir Inc
- Anima Biotech Inc
- Aridis Pharmaceuticals Inc
- Ark Biosciences Inc
- Artificial Cell Technologies Inc
- AstraZeneca Plc
- Atea Pharmaceuticals Inc
- Atriva Therapeutics GmbH
- AVM Biotechnology LLC
- Bavarian Nordic A/S
- Beijing Advaccine Biotechnology Company Ltd
- BioComo Inc
- Blue Lake Biotechnology Inc
- BlueWillow Biologics Inc
- BravoVax Co Ltd
- Calder Biosciences Inc
- Changchun Bcht Biotechnology Co Ltd
- Cidara Therapeutics Inc
- Clover Biopharmaceuticals
- Codagenix Inc
- Curevac AG
- DBV Technologies SA
- Enanta Pharmaceuticals Inc
- Enyo Pharma SA
- Exopharm Ltd
- F. Hoffmann-La Roche Ltd
- Gene Techno Science Co Ltd
- GlaxoSmithKline Plc
- HanaVax Inc
- Heartland Vaccines LLC
- Humabs BioMed SA
- iBio Inc
- Icosavax Inc
- IDBiologics Inc
- ILiAD Biotechnologies LLC
- Immunwork Inc
- IMV Inc
- Inovio Pharmaceuticals Inc
- Johnson & Johnson
- Karyopharm Therapeutics Inc
- Mabxience Holding SL
- Mapp Biopharmaceutical Inc
- Meissa Vaccines Inc
- Merck & Co Inc
- Moderna Inc
- Mucommune LLC
- Navigen Inc
- NeuClone Pty Ltd
- Neuracle Science Co Ltd
- Novavax Inc
- Oita University Institute of Advanced Medicine Inc
- Pfizer Inc
- Pneumagen Ltd
- Profectus BioSciences Inc
- Prosit Sole Biotechnology (Beijing) Co Ltd
- Revelation Biosciences Inc
- ReViral Ltd
- Riboscience LLC
- Romark Laboratories LC
- Sagimet Biosciences
- Sanofi
- Shandong Danhong Pharmaceutical Co Ltd
- Shionogi & Co Ltd
- Sigmovir Biosystems Inc
- Signia Therapeutics
- TechnoVax Inc
- Themis Bioscience GmbH
- Trimunocor Ltd
- Vault Pharma Inc
- Vaxart Inc
- Viramatix Sdn Bhd
- Viravaxx AG
- Virometix AG
- Visterra Inc
- VLP Biotech Inc
- Wyvern Pharmaceuticals Inc
- X4 Pharmaceuticals Inc
- Zhuhai Trinomab Biotechnology Co Ltd
